leadf
logo-loader
viewFSD Pharma
(
CSE:HUGENASDAQ:HUGE
)

FSD Pharma appoints Adnan Bashir as an independent company director

Bashir, a former general manager of Dubai-based business conglomerate Al Batha group, has more than 14 years of experience in strategic management and operations

FSD Pharma -
FSD Pharma said Bashir was appointed to fill the vacancy on the board following the resignation of Frank Lavelle

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) announced it has appointed Adnan Bashir as an independent member of the company’s board of directors.

Bashir, a former general manager of Dubai-based business conglomerate Al Batha group, has more than 14 years of experience in strategic management and operations.

“Adnan’s wealth of experience will add significant value to our Board. We look forward to working with him as we restore FSD,” FSD Pharma co-chairman Anthony Durkacz said in a statement.

READ: FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy

The company said Bashir was appointed to fill the vacancy on the board following the resignation of Frank Lavelle.

FSD Pharma’s board is now comprised of Anthony Durkacz, Zeeshan Saeed, Nitin Kaushal, Lawrence (Larry) Latowsky, Fernando Cugliari, Donal Carroll and Adnan Bashir. 

FSD Pharma is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201.

The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients.

Contact Sean at sean@proactiveinvestors.com

Quick facts: FSD Pharma

Follow
CSE:HUGE

Price: 1.98 CAD

Market Cap: $70.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to...

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc (CSE:HUGE) (NASDAQ:HUGE) Interim CEO Anthony Durkacz tells Proactive the group is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million). Durkacz says the life sciences...

3 weeks, 5 days ago

2 min read